Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NOTICE OF ANNUAL GENERAL MEETING IN PERPETUA MEDICAL AB (PUBL)

The shareholders of Perpetua Medical AB (publ), reg. no. 556723-6418 (the "Company"), are hereby noticed to attend the Annual General Meeting (the “AGM”) on June 14, 2024 at 11 AM at Clarion Hotel Gillet's premises, Dragarbrunnsgatan 23, Uppsala.Right to participate in the meeting Shareholders who wish to attend the annual general meeting must: · be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on the record date for the meeting, which is Wednesday, June 5, 2024, · notify the Company of their participation so that

A new revolutionary method accelerates the development of sustainable biomaterials from years to minutes

Press release 15 May 2024 A groundbreaking study, published in the scientific journal Advanced Materials, on 6 May 2024, led by researchers of VTT Technical Research Centre of Finland, introduces a transformative approach that integrates synthetic biology with advanced machine learning and computational techniques to significantly accelerate the development of new biomaterials. This method reduces the material development timeline from years to mere minutes, promising rapid advancements in medical and industrial applications."By leveraging the power of AI and synthetic biology, we have

BioStock: CLS launches in France

Clinical Laserthermia Systems has entered into an exclusive distribution agreement with MTEC to market and sell the TRANBERG portfolio in France. The distributor specialises in laser technology and has extensive experience in urology.– The TRANBERG product portfolio perfectly complements our current offering in laser technology in urological oncology, says Eric Girard, CEO of MTEC.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/cls-launches-in-france/ This is a press release from BioStock - Connecting Innovation & Capital. https:

Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585 has been accepted and will be presented at the EHA 2024 Hybrid Congress, in Madrid, June 13–16, 2024.The abstract titled “Superior Selectivity of CS585 to The Prostacyclin Receptor Translates to A New Viable Target for Prevention of Thrombosis”, was authored by L. Stanger, P Yalavarthi, A. Rickenberg, K. Goerger, D. Gilmore and M. Holinstat, at

BEWI – Divestments of properties under sale-leaseback agreements

Reference is made to BEWI ASA’s announcement on 29 September 2023 regarding the company entering into agreements with KMC Properties ASA for the divestments of industrial real estates for approximately EUR 55 million. Today, BEWI announces that the divestments of all properties except one included in this transaction, are now completed. The first part of the transaction was closed in December 2023, and divestment of an additional property was completed in March 2024. As per the end of the first quarter of 2024, approximately EUR 20 million was outstanding, of which approximately half has

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 15 May 2024 at 10:00 EESTDuring the 1 April – 30 April 2024 conversion period there were six conversions and a total of 41,005 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 15 May 2024, and trading in the new R shares will start on 16 May 2024.Breakdown of shares after conversion:A shares     175,938,609R shares     612,681,378Total           788,619,987 Each A share and every ten R shares carry one vote. The total amount of votes after the conversion is at least 237,206,746.For

Interim Report Q1 2024: Revenue growth of 82% in Energy

Company Announcement no. 7/202415 May 2024   Wirtek’s Board of Directors has today approved the interim report for Q1 2024. Below a summary - the detailed report is attached to this announcement. CEO Michael Aaen comments: “We continue to predict nervous markets in 2024 due to high interest rates and a continued uncertain geopolitical situation. Inflation rates are approaching a more normal level in Europe, and we expect to see reduced interest rates and an overall improvement of the market conditions towards the end of 2024. We especially have high expectations to continue

Pagero Compliance Services meet customer challenges head-on

To meet increasing customer demands due to the number of jurisdictions introducing e-invoicing and CTC (continuous transaction controls) obligations multiplying worldwide, Pagero is introducing an updated compliance services offering. This will meet customer needs and help them fulfil the changing regulations, using various tools and service tiers.The emergence of new e-invoicing and CTC regulations globally shows no signs of slowing down . In response, several compliance service tiers have been introduced to help our customers keep up with

First Quarter Report Q1-2024

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2024. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.First quarter financial results 2024 (1 January - 31 March):  · Net revenue was KDKK 0 · Operating result was KDKK -4.079  · Net result was KDKK -2.711 · Cash at bank end of the period was KDKK 15.041 · Earnings per share* was KDKK -0,16 · Solidity** was 95%  The Company has advanced well with its planned activities

Kiilto’s 2023 Sustainability Report has been published

Our sustainability report is a deep dive into how we do things at Kiilto, how we think, how we could improve and why certain things are significant to us. Reporting is a management tool and a means of identifying gaps in processes or meeting the expectations of customers, staff and stakeholders.Open documentation and data-driven results make it possible to question certain practices, or confirm their merits. The sustainability report brings together a wide range of information. Sustainability is not a competition – every action is directed towards the common good. Learning from others and

Safello launches card payouts following approval from Visa and Mastercard

Stockholm, 15 April, 2024 | Safello, the leading cryptocurrency exchange in the Nordics, is launching the opportunity for customers to make payouts to Visa and Mastercard cards upon selling cryptocurrency. This feature provides more options for the platform's customers and improves the overall payout process for sell orders. With this, Safello becomes the first cryptocurrency platform in the Nordics to manage this type of payout flow. In January, Safello launched Swish as a payout method, significantly improving the payout process for sell orders. Safello is now adding yet another payout

Eternali establish woodchip business in northern Brazil

Eternali launches a new business area focused on chipping wood raw material and delivering biomass to customers in northern Brazil. The establishment of the new business area is done with customer orders in place and completed acquisitions of chipping machine and land for a production site in the city of Moju in the state of Pará in northern Brazil. The first delivery to customers will take place after the summer."This is an important step for Eternali," says Andreas Forssell, CEO of Eternali. "We have always planned to evaluate the large domestic market for biomass from woodchips. After

Ordinary Share Buy Back

15 May 2024 KR1 plc (“KR1” or the “Company”) Ordinary Share Buy Back The Directors note the significant discount to net asset value at which the shares currently trade and consider that the share price significantly undervalues the Company's portfolio and prospects. Accordingly, the Board of Directors (“Board”) has resolved to commence share repurchases in the market where it believes this to be in shareholders' interests, noting that share buybacks represent an attractive opportunity to increase the Company's investment exposure to its existing portfolio at reduced costs

Transaction in Own Shares

    15 May 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |14/05/2024|+---------------------------------------------------------------

Trading Statement

15 May 2024 Vesuvius plc - Trading Update   Vesuvius plc, a global leader in molten metal flow engineering and technology, announces the following update for the period 1 January to 30 April 2024. Summary · Performance in the period was in line with our expectations · We maintain our expectations for FY 2024 · Excluding India and EEMEA, Steel markets remained subdued at the beginning of the year, as anticipated · Foundry markets outside of India remained weak, particularly in EU27+UK and North Asia · We continue to perform robustly due to our differentiated

Photocure ASA: Results for the first quarter of 2024

Oslo, Norway, 15 May 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding business development expenses.“Photocure delivered positive

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting at the company's premises on May 14, 2024. A total of 30,133,104 shares were represented at the Annual General Meeting, corresponding to 66.61% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company's website.   Adoption of the accounts The Annual General

Orthex Corporation: Interim Report January–March 2024

Orthex Corporation, Stock exchange release, 15 May 2024 at 9.00 a.m. EESTMomentum builds: strong sales and improving profitability This release is a summary of Orthex Corporation’s Interim Report for the period January–March 2024. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/.January–March 2024 · Invoiced sales amounted to EUR 22.9 million (21.2) · Net sales increased by 7.5% to EUR 22.0 million (20.5) · Adjusted EBITDA was EUR 3.8 million (3.4) · Adjusted EBITA was EUR 2.8

First Camp Group Interim report Q1 2024

First Camp, Scandinavia’s largest campsite chain, increased revenues in the first quarter of 2024 by nine percent vs same period in 2023, adjusted for effects from acquisitions (pro forma) and excluding the positive effect of an earlier Easter and seasonal opening.First quarter 2024 (same quarter last year in brackets) · Total revenue of SEK 104.1 million (81.3) · Pro forma revenue increased with 26% compared to Q1 2023 · Pro forma Adjusted EBITDA amounted to SEK -70.6 million (-76.3) · EBIT amounted to SEK -101.8 million (-114.9) · Cash flow from operating activities of

Implantica publishes Interim Report January – March 2024 (Q1)

RefluxStop™ on path to become standard of care for acid reflux treatmentSignificant events in the first quarter of 2024 · Submitted Premarket Approval (PMA) application for RefluxStop™ to U.S. FDA · First of three modules submitted · Next two modules to be submitted in estimated 2 three-month intervals · One time costs of EUR 2.5 million attributed to the FDA process including the Usability study during Q1 · Completed Human Factors Validation Study with 16 U.S. surgeons as part of the FDA PMA process · 20 U.S. foregut surgeons trained on the RefluxStop procedure

There are no items matching the current filter
There are no more items matching the current filter
Back to top